The news indicates that Evercore ISI Group still believes in the potential of C4 Therapeutics, maintaining an Outperform rating. However, the lowered price target from $20 to $10 suggests a more conservative outlook on the stock's short-term performance. This may lead to mixed reactions from investors, resulting in a neutral short-term impact on the stock price.